Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions

Executive Summary

Novartis' discussions with FDA regarding use of the trade name Zelmac for the irritable bowel syndrome therapy (tegaserod) may lead to the company launching the product under a different name.
Advertisement

Related Content

Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months
FDA Drug Name Guidance Will Address Labeling and Packaging-Related Errors
FDA Drug Name Guidance Will Address Labeling and Packaging-Related Errors
Novartis Starlix Takes Aim At Diabetes Prevention With 8,000-Patient Study
Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted
Novartis Zelmac DTC Ads To Emphasize Relief Of Abdominal Pain, Bloating
Novartis Zelmac DTC Ads To Emphasize Relief Of Abdominal Pain, Bloating
Advertisement
UsernamePublicRestriction

Register

PS037367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel